170 related articles for article (PubMed ID: 34146101)
1. Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
Sarafoglou K; Barnes CN; Huang M; Imel EA; Madu IJ; Merke DP; Moriarty D; Nakhle S; Newfield RS; Vogiatzi MG; Auchus RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4666-e4679. PubMed ID: 34146101
[TBL] [Abstract][Full Text] [Related]
2. Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
Auchus RJ; Sarafoglou K; Fechner PY; Vogiatzi MG; Imel EA; Davis SM; Giri N; Sturgeon J; Roberts E; Chan JL; Farber RH
J Clin Endocrinol Metab; 2022 Feb; 107(3):801-812. PubMed ID: 34653252
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
El-Maouche D; Merke DP; Vogiatzi MG; Chang AY; Turcu AF; Joyal EG; Lin VH; Weintraub L; Plaunt MR; Mohideen P; Auchus RJ
J Clin Endocrinol Metab; 2020 Aug; 105(8):2771-8. PubMed ID: 32589738
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency.
Turcu AF; Spencer-Segal JL; Farber RH; Luo R; Grigoriadis DE; Ramm CA; Madrigal D; Muth T; O'Brien CF; Auchus RJ
J Clin Endocrinol Metab; 2016 Mar; 101(3):1174-80. PubMed ID: 26751191
[TBL] [Abstract][Full Text] [Related]
5. Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
Newfield RS; Sarafoglou K; Fechner PY; Nokoff NJ; Auchus RJ; Vogiatzi MG; Jeha GS; Giri N; Roberts E; Sturgeon J; Chan JL; Farber RH
J Clin Endocrinol Metab; 2023 Oct; 108(11):2871-2878. PubMed ID: 37216921
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin releasing factor-1 receptor antagonism associated with favorable outcomes of male reproductive health biochemical parameters.
Khattab A; Charlton RW
Front Endocrinol (Lausanne); 2023; 14():1127558. PubMed ID: 37284216
[TBL] [Abstract][Full Text] [Related]
7. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.
Debono M; Mallappa A; Gounden V; Nella AA; Harrison RF; Crutchfield CA; Backlund PS; Soldin SJ; Ross RJ; Merke DP
Eur J Endocrinol; 2015 Dec; 173(6):727-37. PubMed ID: 26340969
[TBL] [Abstract][Full Text] [Related]
8. Adrenal progestogen and androgen production in 21-hydroxylase-deficient nonclassic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation.
Sánchez LA; Morán C; Reyna R; Ochoa T; Boots LR; Azziz R
Fertil Steril; 2002 Apr; 77(4):750-3. PubMed ID: 11937128
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.
Auchus RJ; Buschur EO; Chang AY; Hammer GD; Ramm C; Madrigal D; Wang G; Gonzalez M; Xu XS; Smit JW; Jiao J; Yu MK
J Clin Endocrinol Metab; 2014 Aug; 99(8):2763-70. PubMed ID: 24780050
[TBL] [Abstract][Full Text] [Related]
10. Relationships of basal level of serum 17-hydroxyprogesterone with that of serum androstenedione and their stimulated responses to a low dose of ACTH in young adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Kang MJ; Kim SM; Lee YA; Shin CH; Yang SW
J Korean Med Sci; 2011 Nov; 26(11):1454-60. PubMed ID: 22065901
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of nephrolithiasis: an emerging issue in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Chiarito M; Lattanzio C; D'Ascanio V; Capalbo D; Cavarzere P; Grandone A; Aiello F; Pepe G; Wasniewska M; Zoller T; Salerno M; Faienza MF
Endocrine; 2024 May; 84(2):727-734. PubMed ID: 38536547
[TBL] [Abstract][Full Text] [Related]
12. Diurnal salivary androstenedione and 17-hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia.
Adriaansen BPH; Kamphuis JS; Schröder MAM; Olthaar AJ; Bock C; Brandt A; Stikkelbroeck NMML; Lentjes EGWM; Span PN; Sweep FCGJ; Claahsen-van der Grinten HL; van Herwaarden AE
Clin Endocrinol (Oxf); 2022 Jul; 97(1):36-42. PubMed ID: 35150157
[TBL] [Abstract][Full Text] [Related]
13. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia.
Çakir ED; Mutlu FS; Eren E; Paşa AO; Sağlam H; Tarim O
J Clin Res Pediatr Endocrinol; 2012 Jun; 4(2):94-100. PubMed ID: 22672867
[TBL] [Abstract][Full Text] [Related]
14. Steroid 17-Hydroxyprogesterone in Hair Is a Potential Long-Term Biomarker of Androgen Control in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
Auer MK; Krumbholz A; Bidlingmaier M; Thieme D; Reisch N
Neuroendocrinology; 2020; 110(11-12):938-949. PubMed ID: 31711056
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate adrenal androgen secretion with once-a-day corticosteroid therapy for congenital adrenal hyperplasia.
Keenan BS; Eberle AE; Lin TH; Clayton GW
J Pediatr; 1990 Jan; 116(1):133-6. PubMed ID: 2153199
[TBL] [Abstract][Full Text] [Related]
16. Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency.
Carmina E; Lobo RA
Fertil Steril; 1990 Jul; 54(1):79-83. PubMed ID: 2162789
[TBL] [Abstract][Full Text] [Related]
17. Block and Replace-a New Therapeutic Concept in Congenital Adrenal Hyperplasia?
Reisch N
J Clin Endocrinol Metab; 2022 Jan; 107(1):e423-e425. PubMed ID: 34331764
[No Abstract] [Full Text] [Related]
18. Low basal androstenedione levels plus augmented 17alpha-hydroxyprogesterone and low dehydroepiandrosterone sulfate responses to adrenocorticotropic hormone stimulation in patients with adrenal incidentaloma.
Ozgen AG; Bayraktar F; Yilmaz C
Endocr Pract; 2001; 7(6):448-53. PubMed ID: 11747281
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia.
Nella AA; Mallappa A; Perritt AF; Gounden V; Kumar P; Sinaii N; Daley LA; Ling A; Liu CY; Soldin SJ; Merke DP
J Clin Endocrinol Metab; 2016 Dec; 101(12):4690-4698. PubMed ID: 27680873
[TBL] [Abstract][Full Text] [Related]
20. The hypothalamic-pituitary-adrenal axis in partial (late-onset) 21-hydroxylase deficiency.
Feuillan P; Pang S; Schürmeyer T; Avgerinos PC; Chrousos GP
J Clin Endocrinol Metab; 1988 Jul; 67(1):154-60. PubMed ID: 2837498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
